Eli Lilly & Co v. Hybio Pharmaceutical Co Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Eli Lilly & Company (Indiana)
  • Defendant: Hybio Pharmaceutical Co. Limited (China) and Hybio Pharmaceutical (US) Co. Limited (California)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: Eli Lilly & Co. v. Hybio Pharmaceutical Co. Ltd., 1:26-cv-00982, D. Del., 08/06/2026
• Venue Allegations: Venue is alleged to be proper based on Defendants' purposeful availment of Delaware's laws, transacting business in Delaware, and distributing generic pharmaceutical products in the state. For the foreign defendant, venue is also asserted under Federal Rule of Civil Procedure 4(k)(2).
• Core Dispute: Plaintiff alleges that Defendants' filing of Abbreviated New Drug Applications (ANDAs) for generic versions of Mounjaro® and Zepbound® constitutes an act of infringement of nine U.S. patents covering the drug tirzepatide, its formulations, and methods of use.
• Technical Context: The technology relates to tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist used for glycemic control in type 2 diabetes and for chronic weight management.
• Key Procedural History: This lawsuit was filed under the Hatch-Waxman Act, triggered by Defendants' notice to Plaintiff of their ANDA filings containing Paragraph IV certifications. These certifications assert that the patents-in-suit are invalid, unenforceable, or will not be infringed by the proposed generic products. Plaintiff filed this action within the 45-day statutory window, triggering an automatic 30-month stay of FDA approval for Defendants' ANDAs. All asserted patents are listed in the FDA's Orange Book for Mounjaro® and/or Zepbound®.

Case Timeline

Date	Event
2018-06-22	Earliest Priority Date for '820, '623, '755, '756, '404 Patents
2018-07-23	Earliest Priority Date for '987, '382, '758, '740 Patents
2022-05-13	FDA grants Lilly approval for Mounjaro® (tirzepatide)
2022-06-14	U.S. Patent No. 11,357,820 ('820 Patent) is issued
2023-11-08	FDA grants Lilly approval for Zepbound® (tirzepatide)
2024-03-05	U.S. Patent No. 11,918,623 ('623 Patent) is issued
2025-05-13	U.S. Patent No. 12,295,987 ('987 Patent) is issued
2025-07-01	U.S. Patent No. 12,343,382 ('382 Patent) is issued
2025-10-28	U.S. Patent Nos. 12,453,755, 12,453,756, and 12,453,758 ('755, '756, '758 Patents) are issued
2026-05-05	U.S. Patent No. 12,616,740 ('740 Patent) is issued
2026-05-19	U.S. Patent No. 12,629,404 ('404 Patent) is issued
2026-07-14	Date of Defendants' Notice Letters regarding ANDA submissions
2026-08-06	Complaint filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,357,820 ("the '820 Patent") - "GIP/GLP1 Agonist Compositions"

• Issued: June 14, 2022

The Invention Explained

• Problem Addressed: The patent background describes a desire for compositions of the GIP/GLP1 co-agonist peptide tirzepatide that have acceptable stability and provide an acceptable patient experience upon injection, a key consideration for subcutaneously administered drugs (U.S. Pat. No. 11357820, col. 1:23-28).
• The Patented Solution: The invention is a pharmaceutical composition that uses sodium chloride (NaCl) as a tonicity agent and dibasic sodium phosphate. This formulation aims to be approximately isotonic with body fluids, which can reduce the painful stinging sensation sometimes associated with subcutaneous injections U.S. Pat. No. 11,357,820, col. 3:17-29 The patent suggests this specific combination provides both stability and an acceptable injection site experience U.S. Pat. No. 11,357,820, col. 1:4-9
• Technical Importance: Developing stable, well-tolerated liquid formulations is crucial for patient compliance and the commercial viability of injectable peptide drugs like tirzepatide.

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶51
• Essential elements of independent claim 1 include:
  • A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof;
  • NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL; and
  • dibasic sodium phosphate.
• The complaint states that Defendants' products will infringe one or more claims of the '820 Patent Compl. ¶53

U.S. Patent No. 11,918,623 ("the '623 Patent") - "GIP/GLP1 Agonist Compositions"

• Issued: March 5, 2024

The Invention Explained

• Problem Addressed: The patent background identifies obesity as a chronic disorder and notes that tirzepatide is a GIP/GLP1 co-agonist peptide useful in its treatment (U.S. Pat. No. 11918623, col. 1:32-35). The implicit problem is the need for effective methods of using such peptides for obesity.
• The Patented Solution: The invention is a method for treating obesity by administering a specific pharmaceutical composition containing tirzepatide. The claims define the composition by the concentration ranges of its active ingredient (tirzepatide) and key excipients (dibasic sodium phosphate, NaCl, and optionally phenol), which contribute to the formulation's stability and tolerability U.S. Pat. No. 11,918,623, col. 2:4-10
• Technical Importance: This patent claims a specific method of using a defined tirzepatide formulation to treat obesity, a major public health issue, thereby protecting a key therapeutic application of the drug.

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶68
• Essential elements of independent claim 1 include:
  • A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide, or pharmaceutically acceptable salt thereof,
  • wherein the tirzepatide concentration is from about 5 mg/mL to about 30 mg/mL;
  • dibasic sodium phosphate is from about 0.67 to about 2.68 mg/mL;
  • NaCl at a concentration from about 6.2 mg/mL to about 9.5 mg/mL; and
  • optionally comprising from about 3.0 mg/mL to about 7.0 mg/mL phenol.
• The complaint states that Defendants' products will infringe one or more claims of the '623 Patent Compl. ¶70

Multi-Patent Capsule: U.S. Patent No. 12,295,987 ("the '987 Patent")

• Patent Identification: "Methods of Using a GIP/GLP1 Co-agonist for Diabetes," issued May 13, 2025 Compl. ¶27
• Technology Synopsis: The patent describes a method of treating type 2 diabetes using a specific GIP:GLP-1 peptide. The method involves a multi-step dose escalation regimen, starting with a first dose and titrating upwards through second, third, and fourth doses, where the doses are defined as percentages of the final (fourth) dose (U.S. Pat. No. 12295987, claim 1). This titration schedule is intended to manage tolerability while achieving therapeutic effect.
• Asserted Claims: At least independent claim 1 is asserted Compl. ¶87
• Accused Features: The complaint alleges that the proposed labeling for Defendants' ANDA product for Mounjaro® will instruct and encourage the specific dose-escalation regimen for treating type 2 diabetes as claimed in the patent Compl. ¶88

Multi-Patent Capsule: U.S. Patent No. 12,343,382 ("the '382 Patent")

• Patent Identification: "Methods of Using a GIP/GLP1 Co-agonist for Therapy," issued July 1, 2025 Compl. ¶29
• Technology Synopsis: The patent covers a method of treating type 2 diabetes (claim 1) or improving weight management (claim 11) by administering tirzepatide. The method requires an "escalation dose" for at least two weeks followed by a "maintenance dose" for at least two weeks, with specific dosages defined for each phase (U.S. Pat. No. 12343382, claims 1; U.S. Pat. No. 12,343,382, claim 11).
• Asserted Claims: At least independent claims 1 and 11 are asserted Compl. ¶¶106-109
• Accused Features: The complaint alleges that the proposed labeling for Defendants' ANDA products will instruct and encourage the specific dose escalation and maintenance regimens for treating type 2 diabetes and improving weight management as claimed in the patent Compl. ¶107 Compl. ¶109

Multi-Patent Capsule: U.S. Patent No. 12,453,755 ("the '755 Patent")

• Patent Identification: "GIP/GLP1 Agonist Compositions," issued October 28, 2025 Compl. ¶31
• Technology Synopsis: The patent claims a method of treating diabetes by administering a pharmaceutical composition with specific concentration ranges for tirzepatide, dibasic sodium phosphate, NaCl, and an optional phenol preservative. This method-of-use patent is closely related to the composition patent '623, but is directed specifically to treating diabetes (U.S. Pat. No. 12453755, claim 1).
• Asserted Claims: At least independent claim 1 is asserted Compl. ¶129
• Accused Features: The complaint alleges that the proposed labeling for Defendants' ANDA product for Mounjaro® will instruct and encourage treating diabetes by administering the claimed composition Compl. ¶130

Multi-Patent Capsule: U.S. Patent No. 12,453,756 ("the '756 Patent")

• Patent Identification: "GIP/GLP1 Agonist Compositions," issued October 28, 2025 Compl. ¶33
• Technology Synopsis: The patent claims a pharmaceutical composition comprising tirzepatide and a specific concentration range of NaCl, where the final composition has a pH between 6.5 and 7.5. This claim is broader than that of the '820 patent, as it does not require dibasic sodium phosphate (U.S. Pat. No. 12453756, claim 1).
• Asserted Claims: At least independent claim 1 is asserted Compl. ¶148
• Accused Features: The complaint alleges that Defendants' proposed ANDA products are pharmaceutical compositions that meet the limitations of the claim Compl. ¶149

Multi-Patent Capsule: U.S. Patent No. 12,453,758 ("the '758 Patent")

• Patent Identification: "Methods of Using a GIP/GLP1 Co-agonist for Diabetes," issued October 28, 2025 Compl. ¶35
• Technology Synopsis: The patent covers a method of improving weight management using a GIP:GLP-1 peptide with a specific dose-escalation schedule. The method is very similar to that claimed in the '987 patent but is directed to weight management instead of diabetes (U.S. Pat. No. 12453758, claim 1).
• Asserted Claims: At least independent claim 1 is asserted Compl. ¶165
• Accused Features: The complaint alleges that the proposed labeling for Defendants' ANDA product for Zepbound® will instruct and encourage the specific dose-escalation regimen for improving weight management as claimed in the patent Compl. ¶166

Multi-Patent Capsule: U.S. Patent No. 12,616,740 ("the '740 Patent")

• Patent Identification: "Methods of Using a GIP/GLP1 Co-agonist for Therapy," issued May 5, 2026 Compl. ¶37
• Technology Synopsis: The patent claims a method for treating type 2 diabetes or obesity by administering tirzepatide in once-weekly doses. The regimen involves a first dose of 2.5 mg for four weeks, followed by 2.5 mg dose increments to reach a maintenance dose of 5, 10, or 15 mg, with each increased dose administered for at least four weeks (U.S. Pat. No. 12616740, claim 1; U.S. Pat. No. 12,616,740, claim 6).
• Asserted Claims: At least independent claims 1 and 6 are asserted Compl. ¶184 Compl. ¶186
• Accused Features: The complaint alleges that the proposed labeling for Defendants' ANDA products will instruct and encourage the claimed dose-escalation and maintenance regimen for treating type 2 diabetes and obesity Compl. ¶185 Compl. ¶187

Multi-Patent Capsule: U.S. Patent No. 12,629,404 ("the '404 Patent")

• Patent Identification: "GIP/GLP1 Agonist Compositions," issued May 19, 2026 Compl. ¶39
• Technology Synopsis: The patent claims a pharmaceutical composition comprising tirzepatide and NaCl within a specific concentration and pH range, with the explicit limitation that the composition is "free of preservative." This distinguishes it from other formulation patents that allow for preservatives (U.S. Pat. No. 12629404, claim 1).
• Asserted Claims: At least independent claim 1 is asserted Compl. ¶207
• Accused Features: The complaint alleges that Defendants' proposed ANDA products are pharmaceutical compositions meeting the limitations of the claim, including being free of preservative Compl. ¶208

III. The Accused Instrumentality

Product Identification

• The accused instrumentalities are Defendants' "Proposed ANDA Products," which are generic versions of Mounjaro® and Zepbound® autoinjectors containing the active ingredient tirzepatide Compl. ¶1 The ANDA numbers are identified as 221683 and 221684 Compl. ¶1

Functionality and Market Context

• The Proposed ANDA Products are described as sterile solutions for subcutaneous use in various strengths (e.g., 2.5 mg/0.5 mL, 5 mg/0.5 mL) Compl. ¶1 The complaint alleges these products are intended to be used as an adjunct to diet and exercise for improving glycemic control in type 2 diabetes (generic Mounjaro®) and for chronic weight management (generic Zepbound®) Compl. ¶1
• The complaint alleges that if approved, these products will be marketed as competing generic versions of Lilly's branded Mounjaro® and Zepbound® products Compl. ¶1 The basis for the infringement suit is the submission of the ANDAs seeking FDA approval to market these products prior to the expiration of the Asserted Patents, which constitutes a statutory act of infringement (Compl. ¶1; Compl. ¶11). No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

'820 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof;	The complaint alleges Defendants' Proposed ANDA Products are pharmaceutical compositions that comprise tirzepatide.	¶52	col. 3:21-29
NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL;	The complaint alleges the Proposed ANDA Products comprise NaCl at a concentration within the claimed range of 6.2 mg/mL to 9.5 mg/mL.	¶52	col. 1:33-35
and dibasic sodium phosphate.	The complaint alleges the Proposed ANDA Products comprise dibasic sodium phosphate.	¶52	col. 1:40-42

• Identified Points of Contention:
  • Technical Questions: The complaint makes a direct allegation of literal infringement by asserting that the Proposed ANDA Products contain all elements of claim 1 Compl. ¶52 A primary question for the court will be the factual one of whether the composition defined in the ANDA filing matches these claim limitations. The complaint alleges that Defendants' notice letters do not contest that the claims cover the proposed products (Compl. ¶55).
  • Scope Questions: A potential issue for claim construction may be the term "dibasic sodium phosphate." The patent specification refers to "dibasic sodium phosphate heptahydrate" in an example US11357820B2, col. 4:60-61 This raises the question of whether the claim term should be interpreted as limited to a specific hydrated form or if it covers any form of dibasic sodium phosphate.

'623 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide, or pharmaceutically acceptable salt thereof,	The complaint alleges Defendants' proposed labeling for ANDA No. 221684 "instructs and encourages treating obesity" by administering the composition to a human.	¶69	col. 3:5-8
wherein the tirzepatide concentration is from about 5 mg/mL to about 30 mg/mL;	The complaint alleges the proposed product's composition contains tirzepatide in a concentration from about 5 mg/mL to about 30 mg/mL.	¶69	col. 2:5-7
dibasic sodium phosphate is from about 0.67 to about 2.68 mg/mL;	The complaint alleges the proposed product's composition contains dibasic sodium phosphate in a concentration from about 0.67 to about 2.68 mg/mL.	¶69	col. 1:53-55
NaCl at a concentration from about 6.2 mg/mL to about 9.5 mg/mL;	The complaint alleges the proposed product's composition contains NaCl in a concentration from about 6.2 mg/mL to about 9.5 mg/mL.	¶69	col. 1:47-49
and optionally comprising from about 3.0 mg/mL to about 7.0 mg/mL phenol.	The complaint alleges the proposed product's composition optionally comprises phenol in a concentration from about 3.0 mg/mL to about 7.0 mg/mL.	¶69	col. 2:40-42

• Identified Points of Contention:
  • Technical Questions: The central issue for this method claim is one of induced infringement. The key question for the court will be whether the content of the proposed product label for ANDA No. 221684 directs or encourages medical professionals and patients to administer the accused product in a manner that practices all steps of the claimed method Compl. ¶69 Compl. ¶78
  • Scope Questions: The term "about" is used for every concentration range in claim 1. The construction of "about" will be critical in determining the literal scope of the claimed ranges. The court will need to determine how much, if any, deviation from the specified numerical ranges is permissible. This raises the question of whether the concentrations in the accused product, if not identical to the recited numbers, fall within the scope of "about."

V. Key Claim Terms for Construction

• The Term: "dibasic sodium phosphate" (from '820 Patent, claim 1)

• Context and Importance: This term is a required excipient in the claimed composition. Its definition is critical because if construed narrowly, it could provide a path for the Defendant to design around the claim. Practitioners may focus on this term because the patent specification refers to a specific hydrated form, "dibasic sodium phosphate heptahydrate" U.S. Pat. No. 11,357,820, col. 4:60-61, in a stability study example, which may create a dispute over whether the claim is limited to that specific form.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: Claim 1 itself simply recites "dibasic sodium phosphate" without specifying a hydrate, which may support an interpretation covering any form, including anhydrous or other hydrated forms.
  • Evidence for a Narrower Interpretation: The consistent use of "dibasic sodium phosphate heptahydrate" in the patent's examples could be argued to implicitly define the invention as being limited to that specific form, suggesting a narrower construction.

• The Term: "about" (from '623 Patent, claim 1)

• Context and Importance: This term modifies every concentration range in the asserted independent claim. Its construction will be central to determining whether the accused product's formulation literally infringes. If the accused product's concentrations differ even slightly from the recited values, the meaning of "about" will determine if they still fall within the claim's scope.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The term "about" is inherently imprecise and is used by patentees to avoid a strict numerical limitation. A court may look to the context of the invention and the state of the art to determine the range of equivalents a person of ordinary skill would understand the term to cover.
  • Evidence for a Narrower Interpretation: The patent does not provide an explicit definition for "about." A defendant may argue that the precision of the numerical ranges provided (e.g., "0.67 to about 2.68 mg/mL") suggests that "about" should be given a very narrow meaning, allowing for only minor, insignificant variations.

VI. Other Allegations

• Indirect Infringement: The complaint alleges active inducement of infringement for all asserted patents. The basis for this allegation is that Defendants' proposed product labels will instruct and encourage physicians and patients to use the generic products in a manner that directly infringes the method-of-use claims (e.g.,Compl. ¶61; Compl. ¶62). For composition claims, inducement is alleged based on instructing third parties to make, use, or sell the infringing compositions Compl. ¶61 Contributory infringement is also alleged, on the basis that the proposed products are especially made for a patented use and are not suitable for substantial non-infringing use Compl. ¶62 Compl. ¶81
• Willful Infringement: The complaint alleges Defendants had knowledge of the Asserted Patents at the time of their ANDA submissions Compl. ¶44 Knowledge is alleged based on the patents' listing in the FDA's Orange Book and their inclusion in Defendants' own notice letters to Lilly Compl. ¶60 Compl. ¶77 The complaint asserts that Defendants have no reasonable basis to believe their products would not infringe, which may support a claim for willfulness post-filing of the complaint Compl. ¶56 Compl. ¶73

VII. Analyst's Conclusion: Key Questions for the Case

This case presents a multifaceted challenge to Lilly's patent portfolio for tirzepatide. The litigation will likely revolve around three key questions:

1. A core issue for the formulation patents ('820, '756, '404 Patents) will be one of claim construction: Can terms like "dibasic sodium phosphate" be limited to the specific embodiments described in the specification, or will they be given their broader, plain meaning? Similarly, how broadly will the court construe the term "about" in the context of specific concentration ranges?

2. For the method-of-use patents ('623, '987, '382, '755, '758, '740 Patents), a central question will be one of induced infringement: Does the proposed product labeling submitted by Defendants in their ANDAs contain instructions that will inevitably lead healthcare providers and patients to practice the specific dosing and administration regimens claimed in the patents?

3. Underpinning the entire dispute is the question of patent validity: While the complaint focuses on infringement, Defendants' Paragraph IV certifications assert that the patents are invalid. The ultimate resolution of the case will depend on whether Defendants can prove by clear and convincing evidence that the claims are invalid, for instance, on grounds of obviousness or lack of written description, an issue that will be developed through expert testimony and discovery.